Pfohl M, Jornayvaz FR, Fritsche A, et al. - A non-interventional, multi-center, prospective study was designed to investigate the efficacy and safety of initiating basal insulin supported oral therapy (BOT) with insulin glargine 300 U/mL (Gla-300) in individuals with T2D inadequately controlled on oral antidiabetic drugs. For this study, experts enrolled 1,748 individuals over the period of 52 weeks in Germany and Switzerland. After 12 months of Gla-300 treatment, hypoglycaemia incidence and rates remained low; there was no severe or severe nocturnal hypoglycaemia. No changes occurred in body weight. It was observed that in daily clinical practice, initiating a BOT regimen with Gla-300 granted about 60% of 721 German and Swiss patients with poorly controlled T2D to carry out glycaemic control within 12 months. In addition, glycaemic control was achieved with no weight gain or elevated risk of nocturnal or acute hypoglycaemia.